Industry Outlook

The global gene therapy market sizewas valued at USD 7.6 million in 2017. It is estimated to expand at a CAGR of over 19.0% during the forecast period. Increasing number of molecules in the development phase is expected to stoke market growth. It was projected that in 2016, more than 900 molecules are in the development phase that can prove to be an effective treatment for several incurable diseases, which are generally caused by an error in a single gene.

Increasing gene therapy innovations for cardiovascular and rare diseases treatment is one of the key trends driving the market. Rising focus on development of gene therapy treatment for rare diseases is a result of intensifying competition among market players to consolidate their position in the industry.

Gene therapy involves incorporation of an artificial or a modified gene using modified viral vectors that help deliver the gene at intended site of action or even kill the cell that may cause the disease. This treatment is mostly a one-time treatment or requires very few doses of medication to completely cure the disease.

The method of treatment, which was once considered impossible, has now become a trend among big and small companies. A consequence of this has been an upsurge in the number of successful startups, backed by investors in line with big companies. The trends is poised to continue and boost the growth of the market during the forecast period.

Some novel molecules to be used for gene therapy are set to reach the commercialization stage. The growth of the market is largely dependent on key decisions made by manufacturers such as pricing, regulations, and reimbursement for treatment along with payers who help cover treatment costs. However, concerns regarding unethical use of the therapy can hamper growth prospects, especially in developing countries.

The gene therapy market is witnessing an upswing in innovations in various therapeutic fields of medicine. However, oncology is at the forefront in terms of innovation. On the basis of indication, the cancer segment accounted for the leading share of the overall market revenue in 2017. This is due to the high number of pipeline molecules that were registered over the last three years. Rising prevalence of cancer caused due to genetic mutations is also contributing to the growth of the segment. The genetic disorders segment, however, is anticipated to register the highest CAGR during the forecast period.

There are very few drugs in the market that have been approved by various regulatory bodies across the globe. These drugs are considered to change the treatment methods and regimen for rare and orphan diseases, however, their sky high pricing is limiting their commercial success.

For instance, Glybera, the first drug approved for the treatment of LPLD, was a breakthrough in the medical history. However, the drug couldnt be a commercial success due to high pricing at 1.6 million USD at the time of launch and very low prevalence of the disease (1-2 per a million of population).

In 2016, GlaxoSmithKline got another drug Strimvelis approved by European drug regulatory authority for the treatment of ADA-SCID. Other techniques in R&D are likely to witness a significant growth rate in the forecast years due to proven success of approved drugs.

The key element of gene therapy lies in the delivery of modified gene or functioning gene. Delivery systems used should be able to deliver functioning gene to intended cell target through modified viruses, which are considered the best vectors by scientists as viruses are highly evolved in delivering nucleic acid, bypassing the immune system of the host.

Several viruses such as Adeno-associated virus, retrovirus, lentivirus, and herpes simplex virus are modified in labs and are used as carriers for gene therapy drugs. Adenovirus is the most used viral vector followed by Retrovirus due to their reduced immunogenicity. Each of the viruses has its own disadvantage such as toxicity, limited DNA carrying capacity, etc.

Non-Viral vectors are being developed lately that can reduce or eliminate viral toxicity completely, however, none of the non-viral vectors possess ideal vector properties as of now.

Europehas seen two efficient gene therapy molecules after 2010, one was released in 2012 by UniQure N.V and other by GlaxoSmithKline, which were groundbreaking and were approved by the European regulatory body.

The U.S. is estimated to become a leader in terms of revenue as the country more than 64.0% of clinical trials by various big and small companies in the overall clinial trials. Among emerging economies, Russia and China are expected to be at the forefront of the market by a significant margin as they have two approved drugs in the market that can be used for cancer treatment.

Some of the key players are UniQure N.V, Spark Therapeutics LLC, Bluebird Bio, Juno Therapeutics, GlaxoSmithKline, Celgene Corporation, Shire Plc, Sangamo Biosciences, Dimension Therapeutics, Voyager Therapeutics, Human Stem Cell Institute, Bristol Myers Squibb, and Chiesi Farmaceutici S.p.A.

Due to a large number of pipeline molecules in development and intense competition among companies to augment their revenue growth, the market is projected to tread along a healthy growth track. Most of the startups are attracting capital investments to support their research for new molecules and initiate new product development.

Attribute

Details

Base year for estimation

2016

Actual estimates/Historical data

2014 - 2016

Forecast period

2017 - 2025

Market representation

Revenue in USD Million and CAGR from 2017 to 2025

Regional scope

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Country scope

U.S., Canada, Germany, U.K., China, Japan, Brazil, South Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors and trends

15% free customization scope (equivalent to 5 analyst working days)

If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization

This report forecasts revenue growth and provides an analysis of themarket trends in each of the sub-markets from 2014 to 2026. For the purpose of this report, Grand View Research has segmented the global gene therapy market report on the basis of indication, vector type, and region:

Indication Outlook (Revenue, USD Million, 2014 - 2026)

Cancer

Cardio Vascular Diseases

Infectious Diseases

Genetic Disorders

Neuro Disorders

Others

Vector Type Outlook (Revenue, USD Million, 2014 - 2026)

Viral Vectors

Retrovirus

Adenovirus

Adeno-associated virus

Vaccinia virus

Herpes simplex virus

Others

Non-Viral Vectors

Injection of Naked DNA

Lipofection

Others

Regional Outlook (Revenue, USD Million, 2014 - 2026)

North America

Europe

Asia Pacific

Latin America

MEA

See more here:
Gene Therapy Market Share Insights - Grand View Research

Comments are closed.